查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1974190

碳-13市场：按纯度、应用和最终用户划分 - 2026-2032年全球预测

Carbon-13 Market by Purity Level, Application, End-User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 180 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，碳-13 市场价值将达到 3,942 万美元，到 2026 年将成长到 4,415 万美元，到 2032 年将达到 6,353 万美元，复合年增长率为 7.05%。

主要市场统计数据
基准年 2025 3942万美元
预计年份：2026年 4415万美元
预测年份 2032 6353万美元
复合年增长率 (%) 7.05%

本文简要解释了碳-13在分析、临床和工业应用中的战略重要性，以及组织为何需要重新评估其采购和研发重点。

碳-13在分析科学、临床研究和工业监测中发挥着至关重要的作用，它是光谱学、成像和示踪研究的重要稳定同位素。随着实验室和诊所不断扩展富集同位素的应用范围，了解其供应特性、纯度规格和主导需求已成为采购经理和技术团队的策略重点。该同位素特异性的核特性使其能够用于高分辨率核磁共振研究、临床试验中的靶向代谢成像以及高灵敏度的环境追踪，但要全面实现这些目标，需要一套完善的采购和品质保证方法。

技术创新、监管完善和跨学科合作正在共同重新定义碳-13应用领域的供应链、品质期望和创新路径。

近年来，由于技术进步、监管改善和跨学科应用等因素的共同作用，碳-13领域正在经历变革。富集技术和标记化学的突破提高了产品的特异性，并拓展了其应用范围，从而重塑了对科学研究机构和临床应用的需求。同时，监管机构和伦理审查委员会也加强了对临床级材料和可追溯性的审查，迫使供应商实施更严格的文件记录和品管方法。

对美国 2025 年实施的关税变化对营运、采购和供应链产生的连锁影响进行评估，并探讨应对这些影响的策略措施。

美国将于2025年实施的关税调整产生了一系列营运和战略影响，需要整个碳-13价值链上的相关人员认真考虑。短期内，筹资策略已发生转变，采购团队重新评估了供应商组合，以应对不断上涨的到岸成本和日益复杂的合规要求。因此，各组织加快了对替代供应商的认证，优先考虑与稳定合作伙伴签订长期合同，并加强了对总拥有成本（TCO）的审查，以保持预算的可预测性。

可操作的细分信息，阐明纯度阈值和特定应用要求如何影响采购决策、认证通讯协定和技术性能预期。

市场细分为解读碳-13生态系统中的需求驱动因素和技术要求提供了至关重要的背景资讯。根据纯度水平，市场分析将产品分为「低于99%」和「高于99%」两类。这种区分至关重要，因为高灵敏度分析方法和符合监管要求的临床工作流程通常需要高纯度材料。因此，实验室和临床机构的采购团队在需要纯度高于99%的材料时，通常会采用严格的合格通讯协定；而在研究机构中，如果成本效益是首要考虑因素，则可接受纯度低于99%的材料用于探索性分析。

决定供应韧性、监管合规性和伙伴关係策略的区域动态和营运现实在美洲、欧洲、中东和非洲以及亚太地区各不相同。

区域趋势影响各组织如何保障物资供应、管理物流以及因应法规结构。在美洲，成熟的研究机构和临床网络构成了集中的需求中心，这些中心与本地化的製造和分销能力相结合，支撑着相对灵活的供应链，能够满足日常需求。然而，不同司法管辖区的物流限制和监管差异仍然会为跨境计划带来复杂性，因此提前规划对于避免延误至关重要。

企业策略和竞争行为揭示了在 Carbon 13 生态系统中，投资、品质保证和伙伴关係模式正在创造可持续竞争优势的领域。

在碳-13价值链中占据领先地位的企业，面临着由产品品质、合规能力以及与终端用户场所的接近性等因素决定的激烈竞争。许多公司正在投资扩大高纯度生产线，并实施更完善的可追溯性系统，以满足临床和诊断客户的文件要求。同时，与学术实验室和临床研究机构建立策略合作伙伴关係也日益普遍，从而能够共同开发标记化合物和特定应用配方，进而加速碳-13的应用推广。

经营团队和采购人员采取以行动为导向、优先考虑的措施，以增强供应韧性，使技术规范与监管要求保持一致，并加快碳-13应用的可靠部署。

产业领导者应采取多层次策略，从碳-13应用中挖掘策略价值，同时降低供应中断风险。首先，应拓宽供应商选择标准，纳入符合严格品质标准的区域製造商和替代生产商。这将减少对单一供应商的依赖，并在主要供应管道受限时缩短回应时间。其次，应在采购流程和实验设计中实施以纯度为导向的规格把关，明确产品特性与应用风险状况和监管要求相匹配，从而避免代价高昂的后期修改。

高度透明的研究途径，明确概述了与关键专家的咨询、实验室检验、监管审查和三角分析，以获得关于碳-13的可靠见解。

支持这些发现的研究结合了与关键相关人员的定性对话、实验室层面的检验以及文件分析，以确保多角度的观点。研究人员采访了技术负责人、采购专家和监管顾问，以了解营运挑战、认证流程以及应对贸易和关税趋势的策略措施。实验室检验活动包括对同位素纯度对代表性分析方法的影响进行可重复性检验，以及检验不同产品规格相关的功能性影响。

整合关键策略和营运要点，强调技术协调、区域策略和适应性采购如何定义韧性和采用路径。

整体而言，三大现实凸显出来：技术特性的重要性、区域策略对营运存取的影响，以及透过适应性商业模式降低政策衝击主导的风险。高纯度要求和应用主导的需求需要严格的合格和文件编制流程，而製造、监管和物流方面的区域差异则影响企业采购决策的优先顺序。此外，政策变化和贸易措施凸显了供应商多元化和扩大国内产能作为长期韧性措施的价值。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章：依纯度分類的碳-13市场

  • 低于99%
  • 超过99%

第九章：碳-13市场：依应用领域划分

  • 环境调查
  • 磁振造影
  • 医学诊断
  • 核磁共振（NMR）波谱

第十章：碳-13市场：依最终用户划分

  • 学术机构和研究机构
  • 化学和材料工业
  • 环保组织
  • 医疗/诊断
  • 製药/生物技术

第十一章：碳-13市场：依地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十二章 碳-13市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十三章 碳-13市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十四章：美国碳-13市场

第十五章：中国碳13市场

第十六章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Air Liquide SA
  • Alsachim
  • Avanti Polar Lipids, Inc.
  • BuyIsotope
  • Cambridge Isotope Laboratories, Inc.
  • CK Isotopes Ltd.
  • Eurisotop SA
  • IBA Molecular North America, Inc.
  • Isoflex USA
  • IsoPrime Limited
  • Isotec
  • LGC Standards
  • Linde PLC
  • Medical & Research Chemical Suppliers
  • Nordion, Inc.
  • Oakwood Chemical, Inc.
  • Qmx Laboratories Ltd.
  • Rotem Industries Ltd.
  • Sciex
  • Sercon Limited
  • Shanghai Chemical Industry Research Institute Co., Ltd.
  • Sigma-Aldrich Chemicals LLC
  • Thermo Fisher Scientific Inc.
  • Trace Sciences International, Inc.
  • URENCO Limited
Product Code: MRR-BF4AC2B6EEF8

The Carbon-13 Market was valued at USD 39.42 million in 2025 and is projected to grow to USD 44.15 million in 2026, with a CAGR of 7.05%, reaching USD 63.53 million by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 39.42 million
Estimated Year [2026] USD 44.15 million
Forecast Year [2032] USD 63.53 million
CAGR (%) 7.05%

A concise orientation explaining the strategic importance of Carbon-13 across analytical, clinical, and industrial applications and why organizations must realign sourcing and R&D priorities

Carbon-13 plays a pivotal role across analytical science, clinical research, and industrial monitoring, serving as an essential stable isotope for spectroscopy, imaging, and tracer studies. As laboratories and clinics broaden the application scope for enriched isotopes, the importance of understanding supply characteristics, purity specifications, and application-driven requirements has become a strategic priority for procurement leaders and technical teams. The isotope's unique nuclear properties enable high-resolution nuclear magnetic resonance studies, targeted metabolic imaging in clinical trials, and sensitive environmental tracking, which collectively demand a nuanced approach to sourcing and quality assurance.

Given the growing diversity of end uses, stakeholders must reevaluate their research priorities and procurement frameworks to ensure continuity of supply and compliance with evolving quality standards. In parallel, technical teams must align experimental designs with available isotope specifications to preserve reproducibility and regulatory integrity. Consequently, a clear understanding of operational constraints, supply pathways, and purity-driven performance characteristics will enable organizations to translate laboratory capability into applied outcomes without compromising timeliness or technical fidelity.

How technological advances, regulatory refinement, and cross-sector collaboration are jointly redefining supply, quality expectations, and innovation pathways for Carbon-13 applications

Recent years have seen a confluence of technological advancement, regulatory refinement, and cross-disciplinary adoption that is transforming the Carbon-13 landscape. Breakthroughs in enrichment techniques and labeling chemistries have improved product specificity and expanded feasible use cases, thus reshaping demand profiles across research and clinical communities. At the same time, regulators and institutional review boards have intensified scrutiny on clinical-grade materials and traceability, prompting suppliers to adopt more rigorous documentation and quality management practices.

Furthermore, the diffusion of advanced spectroscopic methods and metabolic imaging has created new points of intersection between academic research and commercial development. This dynamic has incentivized closer collaboration between manufacturers and end users, resulting in co-development agreements and application-focused product lines. In parallel, sustainability considerations and supply-chain resilience efforts are encouraging investment in domestic capabilities and strategic partnerships, which is changing how organizations distribute risk across geographies. As a result, industry participants now navigate a landscape where technical capability, regulatory preparedness, and strategic partnerships jointly determine competitive differentiation.

Assessing the cascading operational, procurement, and supply chain consequences of the United States tariff changes introduced in 2025 and the strategic responses they have prompted

The tariff adjustments introduced in the United States in 2025 have produced a range of operational and strategic effects that require deliberate response from stakeholders across the Carbon-13 value chain. In the immediate term, sourcing strategies shifted as procurement teams reassessed supplier portfolios to manage elevated landed costs and compliance complexity. Consequently, organizations accelerated qualification of alternative suppliers, prioritized long-term contracts with stable counterparties, and increased scrutiny of total cost of ownership to preserve budgetary predictability.

Over time, the tariffs catalyzed more structural responses within the supply base. Some suppliers accelerated investment in localized production capacity or regional partnerships to mitigate tariff exposure and shorten lead times. These moves improved logistical resilience, albeit with transitional costs related to capital deployment and workforce development. Additionally, the regulatory burden associated with cross-border shipments prompted greater investment in documentation systems and customs planning, which contributed to increased administrative overhead for both manufacturers and end users. Taken together, the tariff environment of 2025 encouraged a rebalancing of risk across sourcing networks, fostering a stronger emphasis on supplier diversification, domestic capacity building, and contractual protections that explicitly address tariff-related contingencies.

Actionable segmentation intelligence that clarifies how purity thresholds and application-specific requirements drive sourcing decisions, qualification protocols, and technical performance expectations

Segmentation provides essential context for interpreting demand drivers and technical requirements within the Carbon-13 ecosystem. Based on purity level, market analysis distinguishes between products specified as Less than 99% and those specified as More than 99%, and this distinction matters because high-purity materials are typically required for high-sensitivity analytical methods and regulatory-compliant clinical workflows. As a result, procurement teams for laboratories and clinical sites often enforce stringent qualification protocols when More than 99% purity is required, whereas research environments may accept Less than 99% material for exploratory assays where cost-efficiency is prioritized.

Equally important is segmentation by application, where supply requirements and quality expectations vary across Environmental Research, Magnetic Resonance Imaging, Medical Diagnostics, and Nuclear Magnetic Resonance (NMR) Spectroscopy. Environmental Research deployments prioritize tracer stability and matrix compatibility to ensure reliable field measurements, while Magnetic Resonance Imaging applications require materials that meet clinical-grade traceability and sterility standards. Medical Diagnostics demand both robust quality systems and batch-level documentation to satisfy regulatory pathways, and NMR Spectroscopy depends on consistent isotopic enrichment and minimal contamination to deliver reproducible spectral resolution. Consequently, aligning product specifications with application-specific requirements is central to reducing technical risk and delivering reliable results across end uses.

Regional dynamics and operational realities that determine supply resilience, regulatory alignment, and partnership strategies across the Americas, Europe, Middle East & Africa, and Asia-Pacific

Regional dynamics shape how organizations secure supply, manage logistics, and engage with regulatory frameworks. In the Americas, established research institutions and clinical networks create concentrated demand pockets, which, in tandem with localized manufacturing and distribution capabilities, support relatively responsive supply chains for routine needs. However, logistical constraints and regulatory variability across jurisdictions can still introduce complexity for cross-border projects, and proactive planning is essential to avoid delays.

Europe, Middle East & Africa presents a heterogeneous environment where regulatory harmonization efforts coexist with distinct national frameworks; as a result, suppliers and end users must invest in documentation and quality alignment to ensure market access. Collaborative networks between academic centers and industrial partners in this region often drive innovation, although fragmentation in logistics can affect lead times. In Asia-Pacific, rapid expansion of clinical research capacity and manufacturing competence has increased regional supply options, yet differences in standards and export controls require careful adjudication when establishing long-term procurement relationships. Across all regions, strategic partnerships, regional manufacturing footprints, and tailored regulatory strategies determine the extent to which organizations can achieve resilient and cost-effective supply continuity.

Corporate strategies and competitive behaviors that reveal where investment, quality assurance, and partnership models are creating durable advantages in the Carbon-13 ecosystem

Leading organizations in the Carbon-13 value chain are navigating a competitive environment defined by product quality, regulatory competence, and proximity to end-use centers. Many firms are directing capital toward expanding high-purity production lines and implementing enhanced traceability systems to meet the documentation demands of clinical and diagnostic customers. Concurrently, strategic collaborations with academic laboratories and clinical research organizations are increasingly common, enabling co-development of labeled compounds and application-specific formulations that accelerate adoption.

Market participants are also optimizing commercial models through flexible contracting, including long-term supply agreements and inventory consignment arrangements that stabilize availability for high-priority programs. Quality management and certification remain key differentiators, as they reduce technical barriers for customers entering regulated use cases. In addition, several companies prioritize process innovation to increase yield and reduce impurity profiles, thereby improving product competitiveness without relying solely on price. Overall, successful corporate strategies combine technical excellence with downstream-facing services that support customer validation and application deployment.

Practical, prioritized actions for executives and procurement leaders to fortify supply resilience, align technical specifications with regulatory needs, and accelerate reliable adoption of Carbon-13 applications

Industry leaders should adopt a layered approach to mitigate disruption while unlocking strategic value from Carbon-13 applications. Begin by broadening supplier qualification criteria to include regional manufacturers and alternate producers that can meet rigorous quality standards; this reduces single-source exposure and shortens response time when primary channels are constrained. Next, incorporate purity-driven specification gates into procurement and experimental design so that the team explicitly matches product attributes to application risk profiles and regulatory needs, thereby avoiding costly downstream remediation.

In parallel, invest in contractual provisions that address tariff volatility, including clauses for cost-sharing, allocation, and advance notice periods, which can preserve budget certainty and commercial relationships. Additionally, prioritize partnerships with academic and clinical centers to co-develop application-specific solutions that accelerate time-to-result and reduce internal development burden. Finally, allocate resources to strengthen traceability and quality systems so that clinical, diagnostic, and regulatory stakeholders receive consistent documentation and batch-level assurances; this not only mitigates compliance risk but also enhances credibility with downstream partners and payers.

A transparent research approach describing primary expert engagement, laboratory validation, regulatory review, and triangulated analysis used to generate reliable insights on Carbon-13

The research underpinning these insights combined primary qualitative engagement, laboratory-level validation, and documentary analysis to ensure a multifaceted perspective. Interviews were conducted with technical leads, procurement specialists, and regulatory advisors to capture operational pain points, qualification processes, and strategic responses to trade and tariff dynamics. Laboratory validation activities included reproducibility checks of isotopic purity effects on representative analytical methods to verify the functional consequences associated with different product specifications.

Documentary analysis encompassed a review of regulatory guidance, shipping and customs requirements, and publicly disclosed quality standards to map compliance risk factors and identify best practices. Findings were triangulated across sources to ensure consistency and to reconcile divergent perspectives between suppliers and end users. Where applicable, supply chain mappings were stress-tested against hypothetical disruption scenarios to derive practical mitigation strategies. This combination of methods produced a robust evidence base that supports reproducible conclusions and practical recommendations for stakeholders across the value chain.

Synthesis of the critical strategic and operational takeaways that underscore why technical alignment, regional strategy, and adaptive sourcing define resilience and adoption pathways

In aggregate, the evidence highlights three enduring realities: technical specificity matters, regional strategy influences operational access, and adaptive commercial models reduce exposure to policy-driven shocks. High-purity requirements and application-driven demands necessitate rigorous qualification and documentation practices, while regional differences in manufacturing, regulation, and logistics shape how organizations prioritize sourcing decisions. Moreover, policy shifts and trade measures have underscored the value of supplier diversification and domestic capacity expansion as long-term resilience measures.

Consequently, organizations that combine technical rigor with strategic sourcing, contractual foresight, and collaborative development will be best positioned to harness Carbon-13 for research, clinical, and environmental applications. By operationalizing the recommendations presented, stakeholders can reduce technical risk, strengthen supply continuity, and accelerate the translation of analytical capability into actionable outcomes for science and patient care.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Carbon-13 Market, by Purity Level

  • 8.1. Less than 99%
  • 8.2. More than 99%

9. Carbon-13 Market, by Application

  • 9.1. Environmental Research
  • 9.2. Magnetic Resonance Imaging
  • 9.3. Medical Diagnostics
  • 9.4. Nuclear Magnetic Resonance (NMR) Spectroscopy

10. Carbon-13 Market, by End-User

  • 10.1. Academia & Research Institutions
  • 10.2. Chemicals / Materials Industry
  • 10.3. Environmental Agencies
  • 10.4. Healthcare / Diagnostics
  • 10.5. Pharmaceutical / Biotechnology

11. Carbon-13 Market, by Region

  • 11.1. Americas
    • 11.1.1. North America
    • 11.1.2. Latin America
  • 11.2. Europe, Middle East & Africa
    • 11.2.1. Europe
    • 11.2.2. Middle East
    • 11.2.3. Africa
  • 11.3. Asia-Pacific

12. Carbon-13 Market, by Group

  • 12.1. ASEAN
  • 12.2. GCC
  • 12.3. European Union
  • 12.4. BRICS
  • 12.5. G7
  • 12.6. NATO

13. Carbon-13 Market, by Country

  • 13.1. United States
  • 13.2. Canada
  • 13.3. Mexico
  • 13.4. Brazil
  • 13.5. United Kingdom
  • 13.6. Germany
  • 13.7. France
  • 13.8. Russia
  • 13.9. Italy
  • 13.10. Spain
  • 13.11. China
  • 13.12. India
  • 13.13. Japan
  • 13.14. Australia
  • 13.15. South Korea

14. United States Carbon-13 Market

15. China Carbon-13 Market

16. Competitive Landscape

  • 16.1. Market Concentration Analysis, 2025
    • 16.1.1. Concentration Ratio (CR)
    • 16.1.2. Herfindahl Hirschman Index (HHI)
  • 16.2. Recent Developments & Impact Analysis, 2025
  • 16.3. Product Portfolio Analysis, 2025
  • 16.4. Benchmarking Analysis, 2025
  • 16.5. Air Liquide S.A.
  • 16.6. Alsachim
  • 16.7. Avanti Polar Lipids, Inc.
  • 16.8. BuyIsotope
  • 16.9. Cambridge Isotope Laboratories, Inc.
  • 16.10. CK Isotopes Ltd.
  • 16.11. Eurisotop SA
  • 16.12. IBA Molecular North America, Inc.
  • 16.13. Isoflex USA
  • 16.14. IsoPrime Limited
  • 16.15. Isotec
  • 16.16. LGC Standards
  • 16.17. Linde PLC
  • 16.18. Medical & Research Chemical Suppliers
  • 16.19. Nordion, Inc.
  • 16.20. Oakwood Chemical, Inc.
  • 16.21. Qmx Laboratories Ltd.
  • 16.22. Rotem Industries Ltd.
  • 16.23. Sciex
  • 16.24. Sercon Limited
  • 16.25. Shanghai Chemical Industry Research Institute Co., Ltd.
  • 16.26. Sigma-Aldrich Chemicals LLC
  • 16.27. Thermo Fisher Scientific Inc.
  • 16.28. Trace Sciences International, Inc.
  • 16.29. URENCO Limited

LIST OF FIGURES

  • FIGURE 1. GLOBAL CARBON-13 MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL CARBON-13 MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL CARBON-13 MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL CARBON-13 MARKET SIZE, BY PURITY LEVEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL CARBON-13 MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL CARBON-13 MARKET SIZE, BY END-USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL CARBON-13 MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL CARBON-13 MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL CARBON-13 MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. UNITED STATES CARBON-13 MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 11. CHINA CARBON-13 MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL CARBON-13 MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL CARBON-13 MARKET SIZE, BY PURITY LEVEL, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL CARBON-13 MARKET SIZE, BY LESS THAN 99%, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL CARBON-13 MARKET SIZE, BY LESS THAN 99%, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL CARBON-13 MARKET SIZE, BY LESS THAN 99%, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL CARBON-13 MARKET SIZE, BY MORE THAN 99%, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL CARBON-13 MARKET SIZE, BY MORE THAN 99%, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL CARBON-13 MARKET SIZE, BY MORE THAN 99%, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL CARBON-13 MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL CARBON-13 MARKET SIZE, BY ENVIRONMENTAL RESEARCH, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL CARBON-13 MARKET SIZE, BY ENVIRONMENTAL RESEARCH, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL CARBON-13 MARKET SIZE, BY ENVIRONMENTAL RESEARCH, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL CARBON-13 MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL CARBON-13 MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL CARBON-13 MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL CARBON-13 MARKET SIZE, BY MEDICAL DIAGNOSTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL CARBON-13 MARKET SIZE, BY MEDICAL DIAGNOSTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL CARBON-13 MARKET SIZE, BY MEDICAL DIAGNOSTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL CARBON-13 MARKET SIZE, BY NUCLEAR MAGNETIC RESONANCE (NMR) SPECTROSCOPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL CARBON-13 MARKET SIZE, BY NUCLEAR MAGNETIC RESONANCE (NMR) SPECTROSCOPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL CARBON-13 MARKET SIZE, BY NUCLEAR MAGNETIC RESONANCE (NMR) SPECTROSCOPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL CARBON-13 MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL CARBON-13 MARKET SIZE, BY ACADEMIA & RESEARCH INSTITUTIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL CARBON-13 MARKET SIZE, BY ACADEMIA & RESEARCH INSTITUTIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL CARBON-13 MARKET SIZE, BY ACADEMIA & RESEARCH INSTITUTIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL CARBON-13 MARKET SIZE, BY CHEMICALS / MATERIALS INDUSTRY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL CARBON-13 MARKET SIZE, BY CHEMICALS / MATERIALS INDUSTRY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL CARBON-13 MARKET SIZE, BY CHEMICALS / MATERIALS INDUSTRY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL CARBON-13 MARKET SIZE, BY ENVIRONMENTAL AGENCIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL CARBON-13 MARKET SIZE, BY ENVIRONMENTAL AGENCIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL CARBON-13 MARKET SIZE, BY ENVIRONMENTAL AGENCIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL CARBON-13 MARKET SIZE, BY HEALTHCARE / DIAGNOSTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL CARBON-13 MARKET SIZE, BY HEALTHCARE / DIAGNOSTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL CARBON-13 MARKET SIZE, BY HEALTHCARE / DIAGNOSTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL CARBON-13 MARKET SIZE, BY PHARMACEUTICAL / BIOTECHNOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL CARBON-13 MARKET SIZE, BY PHARMACEUTICAL / BIOTECHNOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL CARBON-13 MARKET SIZE, BY PHARMACEUTICAL / BIOTECHNOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL CARBON-13 MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 39. AMERICAS CARBON-13 MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 40. AMERICAS CARBON-13 MARKET SIZE, BY PURITY LEVEL, 2018-2032 (USD MILLION)
  • TABLE 41. AMERICAS CARBON-13 MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 42. AMERICAS CARBON-13 MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 43. NORTH AMERICA CARBON-13 MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 44. NORTH AMERICA CARBON-13 MARKET SIZE, BY PURITY LEVEL, 2018-2032 (USD MILLION)
  • TABLE 45. NORTH AMERICA CARBON-13 MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 46. NORTH AMERICA CARBON-13 MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 47. LATIN AMERICA CARBON-13 MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. LATIN AMERICA CARBON-13 MARKET SIZE, BY PURITY LEVEL, 2018-2032 (USD MILLION)
  • TABLE 49. LATIN AMERICA CARBON-13 MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 50. LATIN AMERICA CARBON-13 MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 51. EUROPE, MIDDLE EAST & AFRICA CARBON-13 MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 52. EUROPE, MIDDLE EAST & AFRICA CARBON-13 MARKET SIZE, BY PURITY LEVEL, 2018-2032 (USD MILLION)
  • TABLE 53. EUROPE, MIDDLE EAST & AFRICA CARBON-13 MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 54. EUROPE, MIDDLE EAST & AFRICA CARBON-13 MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 55. EUROPE CARBON-13 MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. EUROPE CARBON-13 MARKET SIZE, BY PURITY LEVEL, 2018-2032 (USD MILLION)
  • TABLE 57. EUROPE CARBON-13 MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 58. EUROPE CARBON-13 MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 59. MIDDLE EAST CARBON-13 MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. MIDDLE EAST CARBON-13 MARKET SIZE, BY PURITY LEVEL, 2018-2032 (USD MILLION)
  • TABLE 61. MIDDLE EAST CARBON-13 MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 62. MIDDLE EAST CARBON-13 MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 63. AFRICA CARBON-13 MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. AFRICA CARBON-13 MARKET SIZE, BY PURITY LEVEL, 2018-2032 (USD MILLION)
  • TABLE 65. AFRICA CARBON-13 MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 66. AFRICA CARBON-13 MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 67. ASIA-PACIFIC CARBON-13 MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. ASIA-PACIFIC CARBON-13 MARKET SIZE, BY PURITY LEVEL, 2018-2032 (USD MILLION)
  • TABLE 69. ASIA-PACIFIC CARBON-13 MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 70. ASIA-PACIFIC CARBON-13 MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL CARBON-13 MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. ASEAN CARBON-13 MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. ASEAN CARBON-13 MARKET SIZE, BY PURITY LEVEL, 2018-2032 (USD MILLION)
  • TABLE 74. ASEAN CARBON-13 MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 75. ASEAN CARBON-13 MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 76. GCC CARBON-13 MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. GCC CARBON-13 MARKET SIZE, BY PURITY LEVEL, 2018-2032 (USD MILLION)
  • TABLE 78. GCC CARBON-13 MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 79. GCC CARBON-13 MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 80. EUROPEAN UNION CARBON-13 MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. EUROPEAN UNION CARBON-13 MARKET SIZE, BY PURITY LEVEL, 2018-2032 (USD MILLION)
  • TABLE 82. EUROPEAN UNION CARBON-13 MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 83. EUROPEAN UNION CARBON-13 MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 84. BRICS CARBON-13 MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 85. BRICS CARBON-13 MARKET SIZE, BY PURITY LEVEL, 2018-2032 (USD MILLION)
  • TABLE 86. BRICS CARBON-13 MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 87. BRICS CARBON-13 MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 88. G7 CARBON-13 MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 89. G7 CARBON-13 MARKET SIZE, BY PURITY LEVEL, 2018-2032 (USD MILLION)
  • TABLE 90. G7 CARBON-13 MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 91. G7 CARBON-13 MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 92. NATO CARBON-13 MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. NATO CARBON-13 MARKET SIZE, BY PURITY LEVEL, 2018-2032 (USD MILLION)
  • TABLE 94. NATO CARBON-13 MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 95. NATO CARBON-13 MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL CARBON-13 MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 97. UNITED STATES CARBON-13 MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 98. UNITED STATES CARBON-13 MARKET SIZE, BY PURITY LEVEL, 2018-2032 (USD MILLION)
  • TABLE 99. UNITED STATES CARBON-13 MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 100. UNITED STATES CARBON-13 MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 101. CHINA CARBON-13 MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 102. CHINA CARBON-13 MARKET SIZE, BY PURITY LEVEL, 2018-2032 (USD MILLION)
  • TABLE 103. CHINA CARBON-13 MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 104. CHINA CARBON-13 MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)